Market Access News | pharmaphorum

News

Pharma CEOs grilled by US Senators over drug prices

Pharma bosses faced a grilling from the US Senate’s Finance Committee over the high price of branded prescription drugs in the US compared with other developed countries.

News

Catalyst defends huge US price hike for rare disease drug

Catalyst Pharmaceuticals has defended hiking the price of the rare disease drug Firdapse (amifampridine) from virtually nothing to more than $300,000 per year following criticism from Senat

News

Final NICE rejection for Biomarin's childhood rare disease d...

After a year of negotiations NICE has confirmed that it is still unable to recommend Biomarin’s Batten disease drug, saying that the company is unable to address concerns about long-term ef

News

Brexit could disrupt medicine supplies for six months - mini...

A no-deal Brexit could disrupt medicines supplies to the UK for at least six months because of delays as they are shipped across the channel, instead of the previously estimated six weeks,

News

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moder

News

Medicare coverage for CAR-T drugs on the horizon

Medicare could soon cover CAR-T therapies under new proposals from the US’ Centers for Medicare & Medicaid Services (CMS), which aim to also gather real-world evidence to eventually inf

Pharma CEOs grilled by US Senators over drug prices

Catalyst defends huge US price hike for rare disease drug

Final NICE rejection for Biomarin's childhood rare disease d...

Brexit could disrupt medicine supplies for six months - mini...

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

Medicare coverage for CAR-T drugs on the horizon

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks